OxyContin Maker Purdue Pharma Exploring Bankruptcy: Source - NBC4 Washington
National & International News
The day’s top national and international news

OxyContin Maker Purdue Pharma Exploring Bankruptcy: Source

Filing for Chapter 11 protection would halt the lawsuits and allow the drug maker to negotiate legal claims with plaintiffs under the supervision of a U.S. bankruptcy judge, sources told NBC News

    processing...

    NEWSLETTERS

    OxyContin Maker Purdue Pharma Exploring Bankruptcy: Source
    Toby Talbot/AP, File
    In this Feb. 19, 2013, file photo, OxyContin pills are arranged for a photo at a pharmacy in Montpelier, Vt.

    OxyContin maker Purdue Pharma is exploring filing for bankruptcy as one of its options to address potentially significant liabilities from thousands of lawsuits alleging the drug maker contributed to the deadly opioid crisis sweeping the U.S., NBC News confirmed through a source familiar with the matter. 

    The deliberations show how Purdue and its wealthy owners, the Sackler family, are under pressure to respond to mounting litigation accusing the pharmaceutical company of misleading doctors and patients about risks associated with prolonged use of its prescription opioids.

     

    Purdue denies the allegations, arguing that the U.S. Food and Drug Administration-approved labels for its opioids carried warnings about the risk of abuse and misuse associated with the drugs.

    Feds’ New Tool to Combat Opioid Crisis: Data

    [NATL] Feds’ New Tool to Combat Opioid Crisis: Data

    Federal officials have a new tool to battle the opioid crisis: data. The Office of National Drug Control Policy's “High Intensity Drug Trafficking Area” program is using a web portal called the “OD Map” to track overdoses caused by opioids in real time. The program will help the agency target high-problem areas with resources and track the sources of the drugs.

    (Published Tuesday, Sept. 25, 2018)

     

    Purdue denies the allegations, arguing that the U.S. Food and Drug Administration-approved labels for its opioids carried warnings about the risk of abuse and misuse associated with the drugs. The Stamford, Connecticut, drug maker has not made any final decisions and could instead continue fighting the lawsuits, sources told NBC News.

    "As a privately held company, it has been Purdue Pharma’s longstanding policy not to comment on our financial or legal strategy," Purdue said in a statement. "We are, however, committed to ensuring that our business remains strong and sustainable."